Australia markets open in 7 hours 15 minutes

Treace Medical Concepts, Inc. (TMCI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.88-0.01 (-0.13%)
At close: 04:00PM EDT
7.51 -0.37 (-4.70%)
After hours: 06:34PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.89
Open7.88
Bid7.86 x 900
Ask7.89 x 400
Day's range7.74 - 8.08
52-week range3.92 - 24.00
Volume446,312
Avg. volume1,459,867
Market cap488.624M
Beta (5Y monthly)0.23
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Treace to Report Second Quarter 2024 Financial Results on August 6, 2024

    PONTE VEDRA, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Tuesday, August 6, 2024. Company management will host a conferenc

  • GlobeNewswire

    Treace to Present at Truist Securities MedTech Conference

    Tuesday, June 18, 2024 at 8:00 am Eastern TimePONTE VEDRA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside

  • GlobeNewswire

    Treace Medical Concepts Reports First Quarter 2024 Financial Results

    PONTE VEDRA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Revenue of $51.1 million in first quarter 2024 increased 21% over same period in 2023Gr